The insider sales are small relative to market cap and are likely driven by tax/estate planning and post-blackout-window liquidity — not a strong bearish signal. Monitor for upcoming quarterly results and pipeline data readouts; the 29% win rate on prior FATE calls suggests the stock is volatile and driven by binary catalysts, not insider activity.
Price Chart
Executive Summary
Two insiders at Fate Therapeutics, including the CEO, sold a combined $204K worth of shares in open-market transactions on August 4, 2026. While the dollar amount is modest relative to the $303M market cap, multi-executive selling at a struggling biotech with a weak historical follow-through on our calls warrants caution.
Key Financial Metrics
Key Facts
- Two insiders sold a total of 82,747 shares for $204,506 in open-market transactions on Aug 4, 2026.
- President & CEO Bahram Valamehr sold 43,947 shares for $108K; board member Cindy Tahl sold 38,800 shares for $95K.
- This is a cluster of C-suite + board sells, suppressing the typical informational signal of insider sales.
- The total sale value of $204K represents ~0.07% of the $303M market cap — below the 0.1% materiality threshold.
- The company's prior quarterly results and pipeline catalysts are not provided in this filing.
Financial Impact
Total insider selling of $204K represents 0.07% of market cap
Risk Factors
- Post-blackout-window selling often clusters for liquidity reasons, reducing informational value.
- Biotech stocks are driven by pipeline catalysts, not insider activity — this filing contains no clinical or regulatory updates.
- The cluster is small in dollar terms and below typical materiality thresholds for insider selling.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-FATE-1786003885323 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | Press Release | $2.57 $2.34 | ▼ −8.95% | ▼ −6.96% | $2.30 (−10.70%) |
Aug 13, 2026 7w ago | 8-K | $2.52 $2.31 | ▼ −8.33% | ▼ −6.59% | $2.30 (−8.93%) |
Aug 5, 2026 8w ago | Insider Cluster | $2.49 $2.42 | ▲ +2.81% | ▲ +3.41% | $2.30 (+7.83%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.97 $3.11 | ▼ −57.87% | ▼ −55.98% | $2.30 (−16.50%) |
Jun 4, 2026 17w ago | 8-K | $1.98 $2.99 | ▲ +51.01% | ▲ +49.15% | $2.30 (+15.91%) |
Jun 1, 2026 17w ago | Press Release | $2.74 $2.70 | ▼ −1.46% | ▼ −0.16% | $2.30 (−16.24%) |
May 13, 2026 20w ago | 8-K | $2.14 $1.97 | ▼ −7.94% | ▼ −7.33% | $2.30 (+7.24%) |
May 11, 2026 20w ago | Press Release | $2.18 $1.90 | ▼ −12.84% | ▼ −12.54% | $2.30 (+5.28%) |
Apr 24, 2026 22w ago | DEFA14A | $1.31 $2.15 | ▲ +64.12% | ▲ +59.17% | $2.30 (+75.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access